PT2860251T - Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento - Google Patents

Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento

Info

Publication number
PT2860251T
PT2860251T PT141944595T PT14194459T PT2860251T PT 2860251 T PT2860251 T PT 2860251T PT 141944595 T PT141944595 T PT 141944595T PT 14194459 T PT14194459 T PT 14194459T PT 2860251 T PT2860251 T PT 2860251T
Authority
PT
Portugal
Prior art keywords
complement
treatment
related disorders
therapeutics useful
aptamer therapeutics
Prior art date
Application number
PT141944595T
Other languages
English (en)
Portuguese (pt)
Inventor
Benedict Claude
Deiner John
Epstein David
Grate Dilara
Chesworth Keene Sara
Kurz Jeffrey
Kurz Markus
Green Mccauley Thomas
Rottman James
Thompson Kristin
Wilson Charles
J Zoltoski Anna
Original Assignee
Archemix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Llc filed Critical Archemix Llc
Publication of PT2860251T publication Critical patent/PT2860251T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
PT141944595T 2004-02-12 2005-02-14 Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento PT2860251T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54454204P 2004-02-12 2004-02-12
US54774704P 2004-02-25 2004-02-25
US58168504P 2004-06-21 2004-06-21
US60804804P 2004-09-07 2004-09-07

Publications (1)

Publication Number Publication Date
PT2860251T true PT2860251T (pt) 2018-06-07

Family

ID=34891329

Family Applications (3)

Application Number Title Priority Date Filing Date
PT141944595T PT2860251T (pt) 2004-02-12 2005-02-14 Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
PT57134967T PT1727567E (pt) 2004-02-12 2005-02-14 Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
PT181569682T PT3385384T (pt) 2004-02-12 2005-02-14 Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT57134967T PT1727567E (pt) 2004-02-12 2005-02-14 Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
PT181569682T PT3385384T (pt) 2004-02-12 2005-02-14 Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento

Country Status (14)

Country Link
US (2) US7538211B2 (US07579456-20090825-P00002.png)
EP (5) EP3385384B1 (US07579456-20090825-P00002.png)
JP (1) JP5242918B2 (US07579456-20090825-P00002.png)
CY (3) CY1114443T1 (US07579456-20090825-P00002.png)
DK (3) DK3385384T3 (US07579456-20090825-P00002.png)
ES (4) ES2531075T3 (US07579456-20090825-P00002.png)
HK (2) HK1183896A1 (US07579456-20090825-P00002.png)
HU (2) HUE050481T2 (US07579456-20090825-P00002.png)
LT (2) LT3385384T (US07579456-20090825-P00002.png)
PL (2) PL2860251T3 (US07579456-20090825-P00002.png)
PT (3) PT2860251T (US07579456-20090825-P00002.png)
SI (2) SI2860251T1 (US07579456-20090825-P00002.png)
TR (1) TR201808488T4 (US07579456-20090825-P00002.png)
WO (1) WO2005079363A2 (US07579456-20090825-P00002.png)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
SG2011071982A (en) * 2001-05-25 2016-09-29 Univ Duke Modulators of pharmacological agents
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
AU2006203792B2 (en) 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20090075342A1 (en) * 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1937719A4 (en) * 2005-08-19 2010-11-24 Novo Nordisk As GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CA2633063A1 (en) * 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids intocells
EP1991275B1 (en) * 2006-03-08 2014-11-05 Archemix LLC Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
MX2009010181A (es) * 2007-03-22 2009-12-04 Novartis Ag Antigenos c5 y usos de los mismos.
EA017770B1 (ru) 2007-04-03 2013-03-29 Биодженерикс Аг Способы лечения с использованием гликопэгилированного g-csf
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
EP2562256A3 (en) * 2007-09-24 2013-06-19 Noxxon Pharma AG C5a binding nucleic acids
US8365727B2 (en) * 2007-11-19 2013-02-05 Carefusion 2200, Inc. Respiratory therapy system with electromechanical driver
WO2009073821A2 (en) * 2007-12-04 2009-06-11 Archemix Corp. Biopolymer-nucleic acid conjugation
CN103497246B (zh) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 缀合的因子viii分子
US20120065254A1 (en) * 2009-03-23 2012-03-15 Noxxon Pharma Ag C5A binding nucleic acids and the use thereof
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
EP2468295A1 (en) * 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
WO2012178083A1 (en) 2011-06-22 2012-12-27 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
SG11201403771SA (en) 2012-01-10 2014-07-30 Noxxon Pharma Ag New c5a binding nucleic acids
EP2666785A1 (en) * 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
ES2780674T3 (es) 2012-11-15 2020-08-26 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP3473272A1 (en) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
IL258525B2 (en) 2015-10-07 2023-03-01 Apellis Pharmaceuticals Inc Dosing regimens
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
CA3058023A1 (en) 2017-04-03 2018-10-11 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
EP3606465A4 (en) 2017-04-07 2021-03-24 Apellis Pharmaceuticals, Inc. DOSING PLANS, ASSOCIATED COMPOSITIONS AND PROCEDURES
US10450345B2 (en) 2017-06-09 2019-10-22 General Electric Company Method of isolation of polypeptide-aptamer-polymer conjugates
CN111201241A (zh) 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
RU2703799C1 (ru) * 2018-05-31 2019-10-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Днк-аптамеры, взаимодействующие с протромбином
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
JP2023525581A (ja) 2020-05-15 2023-06-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体の活性化を検出するための細胞外小胞の使用方法、並びに補体性疾患の処置を評価及び／又は監視するためのその使用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4959309A (en) 1983-07-14 1990-09-25 Molecular Diagnostics, Inc. Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
GB2181661B (en) 1985-10-22 1989-09-20 Nat Res Dev Improvements in or relating to apparatus for removing settled sludge from liquid
US4935363A (en) 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5070010A (en) 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
AU7662091A (en) 1990-03-21 1991-10-21 Isis Pharmaceuticals, Inc. Reagents and methods for modulating gene expression through rna mimicry
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5648214A (en) 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5459015A (en) 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5635615A (en) 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5674685A (en) 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5763173A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
EP1493825A3 (en) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5668264A (en) 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
AU8547691A (en) 1990-09-21 1992-04-15 Fred Hutchinson Cancer Research Center Protein sequence-specific oligonucleotide sequences
DE69123979T2 (de) 1990-10-12 1997-04-30 Max Planck Gesellschaft Abgeänderte ribozyme
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
AU1456092A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
TW239160B (US07579456-20090825-P00002.png) * 1992-10-27 1995-01-21 Procter & Gamble
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5817635A (en) 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US6207816B1 (en) 1995-06-02 2001-03-27 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to growth factors
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
ATE420202T1 (de) 1995-06-07 2009-01-15 Gilead Sciences Inc Nukleinsäure liganden die dna-polymerase binden und inhibieren
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
WO1998018480A1 (en) 1996-10-25 1998-05-07 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US6329145B1 (en) * 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
EP1383782A1 (en) * 2001-03-26 2004-01-28 Sirna Therpeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
JP2005533794A (ja) * 2002-06-18 2005-11-10 アーケミックス コーポレイション アプタマー−毒素分子およびこれを使用する方法
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders

Also Published As

Publication number Publication date
CY1120384T1 (el) 2019-07-10
TR201808488T4 (tr) 2018-07-23
DK3385384T3 (da) 2020-06-29
PT3385384T (pt) 2020-06-30
US20070048248A1 (en) 2007-03-01
WO2005079363A3 (en) 2009-05-14
ES2429442T3 (es) 2013-11-14
PT1727567E (pt) 2013-10-14
DK1727567T3 (da) 2013-10-14
ES2808955T3 (es) 2021-03-02
US7579456B2 (en) 2009-08-25
JP2007527714A (ja) 2007-10-04
LT2860251T (lt) 2018-07-10
EP2860251A1 (en) 2015-04-15
CY1123503T1 (el) 2022-03-24
US20060105980A1 (en) 2006-05-18
EP1727567B1 (en) 2013-07-03
SI3385384T1 (sl) 2020-12-31
DK2860251T3 (en) 2018-06-06
HK1183896A1 (en) 2014-01-10
EP3385384A1 (en) 2018-10-10
CY1114443T1 (el) 2016-08-31
EP2578683B1 (en) 2014-11-26
EP1727567A4 (en) 2010-10-13
HUE050481T2 (hu) 2020-12-28
PL2860251T3 (pl) 2019-02-28
US7538211B2 (en) 2009-05-26
ES2531075T3 (es) 2015-03-10
EP1727567A2 (en) 2006-12-06
WO2005079363A2 (en) 2005-09-01
LT3385384T (lt) 2020-09-25
EP2578683A1 (en) 2013-04-10
PL3385384T3 (pl) 2021-03-08
ES2674129T3 (es) 2018-06-27
JP5242918B2 (ja) 2013-07-24
EP3385384B1 (en) 2020-04-08
SI2860251T1 (en) 2018-07-31
HK1210495A1 (en) 2016-04-22
EP3736335A1 (en) 2020-11-11
EP2578683B9 (en) 2015-04-15
HUE038239T2 (hu) 2018-10-29
EP2860251B1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
HK1256789A1 (zh) 用於治療補體-相關失調的適體治療
HK1210495A1 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
EP1957462A4 (en) NEW 2-AMINO-HETEROCYCLES USEFUL FOR THE TREATMENT OF ABETA-RELATED DISEASES
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
HK1170429A1 (en) Alpha aminoamide derivatives useful in the treatment of cognitive disorders
BRPI0809272A2 (pt) Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
IL190969A0 (en) Pyrazoles useful in the treatment of inflammation
HK1146221A1 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
GB2442365B (en) Methods of determining compounds useful in the treatment of bipolar disorders
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
SI1727567T1 (sl) Aptamerni terapevtiki, uporabni v zdravljenju s komplementom povezanih motenj
GB0513413D0 (en) The treatment of inflammatory disorders and pain
ZA200904249B (en) New combination for use in the treatment of inflammatory disorders
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
GB0502596D0 (en) The treatment of inflammatory disorders and pain
IL229577A0 (en) New amino-sugars and their use for the treatment of genetic diseases
GB0406017D0 (en) The treatment of inflammatory disorders
GB0406016D0 (en) The treatment of inflammatory disorders
GB0422880D0 (en) The treatment of inflammatory disorders
IL194370A0 (en) Novel aminoglycosides and uses thereof in the treatment of genetic disorders